We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Melflufen

News List

Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology firstwordpharma
May 20, 2021
The clinical data presentations include updates on Oncopeptides' ANCHOR and LIGHTHOUSE studies as well as a pooled analysis of the O-12-M1 and HORIZON studies in patients who have been exposed to or become refractory to prior alkylators.
FDA Grants Priority Review of Melflufen for Triple-Class Refractory Multiple Myeloma americanpharmaceuticalreview
September 02, 2020
Oncopeptides has announced the US Food and Drug Administration (FDA) has granted priority review for Oncopeptides' New Drug Application seeking approval of melflufen (INN melphalan flufenamide), in combination with dexamethasone for ...